The Company’s preliminary cash and cash equivalents balance was approximately $11.3 million as of the end of the fiscal year on March 31, 2025. Organovo’s preliminary net cash utilization during the ...

A study published in the American Journal of Gastroenterology reveals significant disparities in health care utilization ...

The Crohn's & Colitis Diet Information & Recipe Book aims to help people support their gut health with tasty and delicious ...

Vitamin D is well-known for supporting strong bones and a healthy immune system, but new research suggests it could also play ...

Demi Ricario considers herself both a foodie and a globe-trotter. The “travel bug,” she tells SELF, hit her when she was 15 ...

ABIVAX is a French biotech with a novel ulcerative colitis treatment in phase 3 trials. Click here to find out why I am ...

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment ...

Review identifies common food additives in ultra-processed foods—particularly emulsifiers like carrageenan and polysorbate 80 ...

Based on the currently available funds and the expected reimbursement of the research tax credits (CIR) from 2024 in the second half of 2025 amounting to EUR 5.7M, Abivax expects to be able to finance ...

Almost half of people who died with inflammatory bowel disease (IBD) died prematurely, according to a study published in the ...